MX2019008564A - Composiciones inmunogenicas para su uso en vacunas neumococicas. - Google Patents

Composiciones inmunogenicas para su uso en vacunas neumococicas.

Info

Publication number
MX2019008564A
MX2019008564A MX2019008564A MX2019008564A MX2019008564A MX 2019008564 A MX2019008564 A MX 2019008564A MX 2019008564 A MX2019008564 A MX 2019008564A MX 2019008564 A MX2019008564 A MX 2019008564A MX 2019008564 A MX2019008564 A MX 2019008564A
Authority
MX
Mexico
Prior art keywords
immunogenic compositions
pneumococcal vaccines
pneumococcal
present
pneumoniae
Prior art date
Application number
MX2019008564A
Other languages
English (en)
Other versions
MX392525B (es
Inventor
Ute Jansen Kathrin
William Pride Michael
Cooper David
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MX2019008564A publication Critical patent/MX2019008564A/es
Publication of MX392525B publication Critical patent/MX392525B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

Un objeto de la presente invención es proporcionar composiciones inmunogénicas para protección contra S.pneumoniae, en particular contra El grupo sérico 18 de S. pneumoniae, mientras que limita el número de conjugados. La presente invención por lo tanto se relaciona con composiciones inmunogénicas novedosas para su uso en vacunas neumocócicas y en vacunación de sujetos humanos, en particular lactantes y personas mayores, contra infecciones neumocócicas utilizando las composiciones inmunogénicas.
MX2019008564A 2017-01-20 2018-01-05 Composiciones inmunogenicas para su uso en vacunas neumococicas MX392525B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762448485P 2017-01-20 2017-01-20
PCT/IB2018/050084 WO2018134693A1 (en) 2017-01-20 2018-01-05 Immunogenic compositions for use in pneumococcal vaccines

Publications (2)

Publication Number Publication Date
MX2019008564A true MX2019008564A (es) 2019-09-19
MX392525B MX392525B (es) 2025-03-12

Family

ID=61028107

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019008564A MX392525B (es) 2017-01-20 2018-01-05 Composiciones inmunogenicas para su uso en vacunas neumococicas

Country Status (18)

Country Link
US (2) US11413344B2 (es)
EP (1) EP3570879B1 (es)
JP (1) JP7120767B2 (es)
KR (1) KR102459629B1 (es)
CN (1) CN110198735A (es)
AU (1) AU2018208844B2 (es)
BR (1) BR112019014833A2 (es)
CA (1) CA3050622A1 (es)
DK (1) DK3570879T3 (es)
ES (1) ES2911490T3 (es)
HR (1) HRP20220573T1 (es)
HU (1) HUE059252T2 (es)
IL (1) IL268168A (es)
MX (1) MX392525B (es)
PL (1) PL3570879T3 (es)
RU (1) RU2762723C2 (es)
SI (1) SI3570879T1 (es)
WO (1) WO2018134693A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112016015835B1 (pt) * 2014-01-21 2023-12-26 Pfizer Inc Processo de preparação de conjugados compreendendo polissacarídeos capsulares de streptococcus pneumoniae
KR102800419B1 (ko) * 2015-07-21 2025-04-25 화이자 인코포레이티드 접합된 캡슐형 사카라이드 항원을 포함하는 면역원성 조성물, 그를 포함하는 키트 및 그의 용도
EP3824906A1 (en) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations
US11951165B2 (en) 2016-12-30 2024-04-09 Vaxcyte, Inc. Conjugated vaccine carrier proteins
KR20190103256A (ko) 2016-12-30 2019-09-04 수트로박스, 인코포레이티드 비자연 아미노산을 갖는 폴리펩타이드-항원 접합체
MX392525B (es) 2017-01-20 2025-03-12 Pfizer Composiciones inmunogenicas para su uso en vacunas neumococicas
WO2018144439A1 (en) 2017-01-31 2018-08-09 Merck Sharp & Dohme Corp. Methods for making polysaccharide-protein conjugates
BR112019017560A2 (pt) 2017-02-24 2020-04-07 Merck Sharp & Dohme intensificação da imunogenicidade dos conjugados de polissacarídeo-proteína de streptococcus pneumoniae
US10729763B2 (en) 2017-06-10 2020-08-04 Inventprise, Llc Mixtures of polysaccharide-protein pegylated compounds
CA3074703A1 (en) 2017-09-07 2019-03-14 Merck Sharp & Dohme Corp. Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates
US11389540B2 (en) 2017-09-07 2022-07-19 Merck Sharp & Dohme Llc Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates
MX2020005779A (es) 2017-12-06 2020-10-28 Merck Sharp & Dohme Composiciones que comprenden conjugados de polisacarido de streptococcus pneumoniae con proteina y metodos de uso de estos.
JP7489324B2 (ja) 2018-04-30 2024-05-23 メルク・シャープ・アンド・ドーム・エルエルシー リオスフィアから肺炎連鎖球菌莢膜多糖類キャリアタンパク質コンジュゲートを生産する方法
KR20210005158A (ko) 2018-04-30 2021-01-13 머크 샤프 앤드 돔 코포레이션 스트렙토코쿠스 뉴모니아에 피막 폴리사카라이드 담체 단백질 접합체를 제조하는 방법
KR102827174B1 (ko) 2018-04-30 2025-06-27 머크 샤프 앤드 돔 엘엘씨 디메틸술폭시드 중의 동결건조된 돌연변이체 디프테리아 독소의 균질 용액을 제공하는 방법
KR20240169145A (ko) 2018-12-19 2024-12-02 머크 샤프 앤드 돔 엘엘씨 스트렙토코쿠스 뉴모니아에 폴리사카라이드-단백질 접합체를 포함하는 조성물 및 그의 사용 방법
JPWO2022054207A1 (es) 2020-09-10 2022-03-17
CA3200968A1 (en) 2020-11-10 2022-05-19 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2024241172A2 (en) 2023-05-19 2024-11-28 Glaxosmithkline Biologicals Sa Methods for eliciting an immune response to respiratory syncycial virus and streptococcus pneumoniae infection

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4709017A (en) 1985-06-07 1987-11-24 President And Fellows Of Harvard College Modified toxic vaccines
US4950740A (en) 1987-03-17 1990-08-21 Cetus Corporation Recombinant diphtheria vaccines
GB8815795D0 (en) 1988-07-02 1988-08-10 Bkl Extrusions Ltd Glazing bead
NZ230747A (en) 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
DE3841091A1 (de) 1988-12-07 1990-06-13 Behringwerke Ag Synthetische antigene, verfahren zu ihrer herstellung und ihre verwendung
EP0378881B1 (en) 1989-01-17 1993-06-09 ENIRICERCHE S.p.A. Synthetic peptides and their use as universal carriers for the preparation of immunogenic conjugates suitable for the development of synthetic vaccines
EP0482068A1 (en) 1989-07-14 1992-04-29 American Cyanamid Company Cytokine and hormone carriers for conjugate vaccines
IT1237764B (it) 1989-11-10 1993-06-17 Eniricerche Spa Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici.
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
EP0471177B1 (en) 1990-08-13 1995-10-04 American Cyanamid Company Filamentous hemagglutinin of bordetella pertussis as a carrier molecule for conjugate vaccines
KR950700081A (ko) 1992-02-11 1995-01-16 W 로우 죤 이중 캐리어 면역원성 구성물
IT1262896B (it) 1992-03-06 1996-07-22 Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
WO1993021769A1 (en) 1992-05-06 1993-11-11 President And Fellows Of Harvard College Diphtheria toxin receptor-binding region
EP0761231B1 (en) 1992-06-25 2000-01-12 SMITHKLINE BEECHAM BIOLOGICALS s.a. Vaccine composition containing adjuvants
IL102687A (en) 1992-07-30 1997-06-10 Yeda Res & Dev Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them
ATE280235T1 (de) 1993-03-05 2004-11-15 Wyeth Corp Plasmid zur herstellung von crm-protein und diphtherie-toxin
ES2162139T5 (es) 1993-03-23 2008-05-16 Smithkline Beecham Biologicals S.A. Composiciones de vacuna que contienen monofosforil-lipido a 3-o-desacilado.
ATE254475T1 (de) 1993-09-22 2003-12-15 Jackson H M Found Military Med Verfahren zur aktivierung von löslichem kohlenhydraten durch verwendung von neuen cyanylierungsreagenzien, zur herstellung von immunogenischen konstrukten
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US5917017A (en) 1994-06-08 1999-06-29 President And Fellows Of Harvard College Diphtheria toxin vaccines bearing a mutated R domain
US6455673B1 (en) 1994-06-08 2002-09-24 President And Fellows Of Harvard College Multi-mutant diphtheria toxin vaccines
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
EP0772619B2 (en) 1994-07-15 2010-12-08 The University of Iowa Research Foundation Immunomodulatory oligonucleotides
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
EP0814833B1 (en) 1995-03-22 2003-05-28 Henry M. Jackson Foundation For The Advancement Of Military Medicine Producing immunogenic constructs using soluble carbohydrates activated via organic cyanylating reagents
GB9513261D0 (en) 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines
AUPO517897A0 (en) 1997-02-19 1997-04-11 Csl Limited Chelating immunostimulating complexes
AU738513B2 (en) 1997-02-28 2001-09-20 University Of Iowa Research Foundation, The Use of nucleic acids containing unmethylated CpG dinucleotide in the treatment of LPS-associated disorders
US6299881B1 (en) 1997-03-24 2001-10-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts
DE69838294T2 (de) 1997-05-20 2009-08-13 Ottawa Health Research Institute, Ottawa Verfahren zur Herstellung von Nukleinsäurekonstrukten
GB9712347D0 (en) 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
GB9713156D0 (en) 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines
DE69838992T2 (de) 1997-09-05 2008-12-24 Glaxosmithkline Biologicals S.A., Rixensart Öl-in-Wasser Emulsionen mit Saponinen
US6303114B1 (en) 1998-03-05 2001-10-16 The Medical College Of Ohio IL-12 enhancement of immune responses to T-independent antigens
ES2284247T3 (es) 1998-04-03 2007-11-01 University Of Iowa Research Foundation Metodos y productos para estimular el sistema inmunitario usando oligonucleotidos y citoquinas inmunoterapeuticos.
WO1999052549A1 (en) 1998-04-09 1999-10-21 Smithkline Beecham Biologicals S.A. Adjuvant compositions
GB9817052D0 (en) 1998-08-05 1998-09-30 Smithkline Beecham Biolog Vaccine
CZ301212B6 (cs) 1998-10-16 2009-12-09 Smithkline Beecham Biologicals S. A. Vakcinacní prostredek
DK1140157T3 (da) 1998-12-21 2009-06-08 Medimmune Inc Streptococcus pneumoniae-proteiner og immunogene fragmenter til vacciner
ATE394489T1 (de) 1998-12-23 2008-05-15 Id Biomedical Corp Streptococcus antigene
AUPP807399A0 (en) 1999-01-08 1999-02-04 Csl Limited Improved immunogenic lhrh composition and methods relating thereto
EP1150710B1 (en) 1999-02-17 2010-04-21 Csl Limited Immunogenic complexes and methods relating thereto
US6936258B1 (en) 1999-03-19 2005-08-30 Nabi Biopharmaceuticals Staphylococcus antigen and vaccine
EP1162999B1 (en) 1999-03-19 2006-11-29 Glaxosmithkline Biologicals S.A. Vaccine against Streptococcus pneumoniae
JP2002541808A (ja) 1999-04-09 2002-12-10 テクラブ， インコーポレイテッド ポリサッカリド結合体ワクチンのための組換えトキシンａタンパク質キャリア
TR200103018T2 (tr) 1999-04-19 2002-02-21 Beecham Biologicals S.A. Smithkline İmmünostimülatör oligonükleotid ve saponin içeren katkı bileşikleri.
JP2003509473A (ja) 1999-09-24 2003-03-11 スミスクライン ビーチャム バイオロジカルズ ソシエテ アノニム ワクチン
KR20020048942A (ko) 1999-09-24 2002-06-24 장 스테판느 폴리옥시에틸렌 알킬 에테르 또는 에스테르 및 하나이상의 비이온성 계면활성제를 포함하는 애쥬번트
GB0007432D0 (en) 2000-03-27 2000-05-17 Microbiological Res Authority Proteins for use as carriers in conjugate vaccines
EA006232B1 (ru) 2000-06-20 2005-10-27 Ай Ди Биомедикал Корпорейшн Стрептококковые антигены
AU2002309706A1 (en) 2001-05-11 2002-11-25 Aventis Pasteur, Inc. Novel meningitis conjugate vaccine
EP1425040A2 (en) 2001-09-14 2004-06-09 Cytos Biotechnology AG In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles
AU2002351623A1 (en) 2001-12-20 2003-07-09 Shire Biochem Inc. Streptococcus antigens
DE602004010376T2 (de) 2003-03-13 2008-10-23 Glaxosmithkline Biologicals S.A. Verfahren zur reinigung von bakteriellem cytolysin
EP1603950A2 (en) 2003-03-17 2005-12-14 Wyeth Holdings Corporation Mutant cholera holotoxin as an adjuvant and an antigen carrier protein
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
JP2008506683A (ja) 2004-07-18 2008-03-06 コーリー ファーマシューティカル グループ， リミテッド 先天免疫応答を誘導するための方法および組成物
KR20100018029A (ko) 2004-07-18 2010-02-16 씨에스엘 리미티드 면역자극 복합체 및 향상된 인터페론-감마 반응을 유도하기 위한 올리고뉴클레오티드 제제
GB0421083D0 (en) 2004-09-22 2004-10-27 Glaxosmithkline Biolog Sa Purification process
US7955605B2 (en) 2005-04-08 2011-06-07 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
CN104815327A (zh) * 2005-04-08 2015-08-05 惠氏有限责任公司 多价肺炎球菌多糖-蛋白质缀合物组合物
US20070184072A1 (en) 2005-04-08 2007-08-09 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition
US7709001B2 (en) 2005-04-08 2010-05-04 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
AU2006234984B2 (en) 2005-04-08 2011-10-13 Wyeth Separation of contaminants from Streptococcus pneumoniae polysaccharide by pH manipulation
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
PL3017827T3 (pl) 2005-12-22 2019-04-30 Glaxosmithkline Biologicals Sa Szczepionka z koniugatem polisacharydu pneumokokowego
PT2074221E (pt) 2006-10-10 2010-09-06 Wyeth Llc Métodos melhorados para a separação de polissacáridos tipo 3 de streptococcus pneumoniae
PT2129693T (pt) 2007-03-23 2017-02-14 Wyeth Llc Processo de purificação abreviado para a produção de polissacáridos capsulares de streptococcus pneumoniae
US9610339B2 (en) 2007-06-26 2017-04-04 Glaxosmithkline Biologicals, S.A. Vaccine comprising Streptococcus pneumoniae capsular polysaccharide conjugates
BRPI1009829A2 (pt) 2009-03-24 2016-11-16 Novartis Ag combinações de proteína de ligação de fator h meningocócico e conjugados de sacarídeos pneumocócicos
KR101450958B1 (ko) 2009-04-30 2014-10-15 콜레이 파마시티컬 그룹, 인코포레이티드 폐렴구균 백신 및 그의 용도
MX2012000158A (es) * 2009-06-29 2012-06-08 Genocea Biosciences Inc Vacunas y composiciones contra streptococcus pneumoniae.
CN102068690A (zh) * 2010-12-31 2011-05-25 北京民海生物科技有限公司 多价肺炎球菌荚膜多糖结合疫苗及其制备方法
IN2015DN00694A (es) 2012-08-16 2015-06-26 Pfizer
CN104870463B (zh) 2012-12-20 2018-09-28 辉瑞公司 糖缀合方法
CN103495161B (zh) 2013-10-08 2019-06-18 江苏康泰生物医学技术有限公司 一种多元肺炎球菌荚膜多糖-蛋白质结合物的混合物及其制备方法
CA2937190A1 (en) * 2014-01-21 2015-07-30 Pfizer Inc. Streptococcus pneumoniae capsular polysaccharides and conjugates thereof
KR20220080201A (ko) * 2014-01-21 2022-06-14 화이자 인코포레이티드 접합된 캡슐 사카라이드 항원을 포함하는 면역원성 조성물 및 그의 용도
CN104069504B (zh) 2014-05-11 2019-09-24 江苏康泰生物医学技术有限公司 一种增强多糖蛋白结合物免疫原性的方法
DK3244917T5 (da) 2015-01-15 2024-10-14 Pfizer Immunogene sammensætninger til anvendelse i pneumokokvacciner
MX392525B (es) 2017-01-20 2025-03-12 Pfizer Composiciones inmunogenicas para su uso en vacunas neumococicas

Also Published As

Publication number Publication date
JP7120767B2 (ja) 2022-08-17
KR102459629B1 (ko) 2022-10-28
CN110198735A (zh) 2019-09-03
BR112019014833A2 (pt) 2020-04-14
HRP20220573T1 (hr) 2022-06-10
WO2018134693A1 (en) 2018-07-26
ES2911490T3 (es) 2022-05-19
RU2019122619A (ru) 2021-02-20
US20230190907A1 (en) 2023-06-22
SI3570879T1 (sl) 2022-06-30
RU2762723C2 (ru) 2021-12-22
US11413344B2 (en) 2022-08-16
US20190343946A1 (en) 2019-11-14
EP3570879A1 (en) 2019-11-27
AU2018208844B2 (en) 2021-02-25
CA3050622A1 (en) 2018-07-26
EP3570879B1 (en) 2022-03-30
MX392525B (es) 2025-03-12
HUE059252T2 (hu) 2022-11-28
RU2019122619A3 (es) 2021-02-20
JP2018115159A (ja) 2018-07-26
IL268168A (en) 2019-09-26
KR20190097176A (ko) 2019-08-20
DK3570879T3 (da) 2022-04-11
AU2018208844A1 (en) 2019-07-11
US12318438B2 (en) 2025-06-03
PL3570879T3 (pl) 2022-06-20

Similar Documents

Publication Publication Date Title
MX2019008564A (es) Composiciones inmunogenicas para su uso en vacunas neumococicas.
MX395525B (es) Composiciones inmunogenicas para usar en vacunas neumococicas.
MX2021000523A (es) Composiciones inmunogenicas que comprenden antigenos sacaridos capsulares conjugados y usos de los mismos.
CO2018000503A2 (es) Composiciones inmunógenas que comprenden antígenos de sacárido capsular conjugados, kits que las comprenden y sus usos
CL2018000319A1 (es) Coadyuvantes basados en aceite (divisional de solicitud 201600650)
CL2019003264A1 (es) Formulaciones para vacunas contra la neoplasia y métodos para preparar las mismas. (divisional solicitud 201703151)
MX2022002106A (es) Formulaciones de vacuna de vial unico.
MX2025002465A (es) Metodos y dispositivos para la preparacion de agentes de contraste de ultrasonido
BR112017022755A2 (pt) formulações de glucopiranosil lipídeo a e alérgeno a amendoim para administração sublingual
BR112014020025A2 (pt) vacinas de subunidade de rotavirus e métodos de produção e uso das mesmas
CL2016000787A1 (es) Composición farmacéutica en forma de comprimido que comprende atazanavir y cobicistat; procedimiento de preparación; y uso de la composición para preparar un medicamento útil para tratar la infección por el virus de inmunodeficiencia humana (vih).
MX2019002552A (es) Composicion que comprende polisacarido capsular neumococico multivalente-proteina transportadora y uso de la misma.
BR112016012435A8 (pt) vacina, e, usos de uma proteína orf2 recombinantemente expressada do circovírus porcino tipo 2
MX2023005221A (es) Composiciones inmunogenicas para uso en vacunas neumococicas.
BR112022002094A2 (pt) Composição imunogênica
MX388528B (es) Vacuna que comprende toxoides de clostridium.
AR095501A1 (es) Vacunas rsv